Pharmaconnect.
Pharmaconnect is an Australian advisory firm working with life sciences companies on partnering, licensing, and capital.
Founded by Dr Richard Treagus, who has personally led and closed transactions with Eli Lilly, Acadia, Wyeth, Boots, Abbott and Orion Pharma.
MBA · MPharmMed · MBChB · BScMed
Identifying counterparties, structuring terms, and closing global out-licensing and in-licensing deals.
Product development, regulatory pathway, and commercialisation strategy for boards and CEOs of ASX-listed and private companies.
Capital raising, M&A support, and investor positioning.
Identifying counterparties, structuring terms, and closing global out-licensing and in-licensing deals.
Product development, regulatory pathway, and commercialisation strategy for boards and CEOs of ASX-listed and private companies.
Capital raising, M&A support, and investor positioning.
Identifying counterparties, structuring terms, and closing global out-licensing and in-licensing deals.
Product development, regulatory pathway, and commercialisation strategy for boards and CEOs of ASX-listed and private companies.
Capital raising, M&A support, and investor positioning.
Richard has spent 30+ years building and running pharmaceutical and medtech businesses across Australia, New Zealand, South Africa, the US and Europe.
As Managing Director and CEO of Acrux Limited (ASX:ACR), he led the company's transformational licensing transaction — the US$335m global deal with Eli Lilly for Axiron® — and delivered Acrux's maiden profit and A$100m dividend in 2010. The same year he was named EY Entrepreneur of the Year (Listed Company category) and has subsequently served on the EY judging panel.
As Executive Chairman of Neuren Pharmaceuticals (ASX:NEU), he migrated the business from New Zealand to Australia, completed multiple capital raises, and repositioned the company around rare and orphan neurodevelopmental indications — a strategy that culminated in the up to US$465m North American licensing deal with Acadia Pharmaceuticals for trofinetide, the foundation of what later became Daybue™.
He currently serves as Executive Chairman of BTC Health (ASX:BTC) and founding Director of Pharmaconnect.
Richard has closed deals with Eli Lilly, Acadia, Wyeth, Boots, Abbott, Orion Pharma, KV Pharma and Avanos Medical.
As Executive Chairman of Neuren Pharmaceuticals (ASX:NEU), he migrated the business from New Zealand to Australia, completed multiple capital raises, and repositioned the company around rare and orphan neurodevelopmental indications — a strategy that culminated in the up to US$465m North American licensing deal with Acadia Pharmaceuticals for trofinetide, the foundation of what later became Daybue™.
He currently serves as Executive Chairman of BTC Health (ASX:BTC) and founding Director of Pharmaconnect.
Richard has closed deals with Eli Lilly, Acadia, Wyeth, Boots, Abbott, Orion Pharma, KV Pharma and Avanos Medical.
As Executive Chairman of Neuren Pharmaceuticals (ASX:NEU), he migrated the business from New Zealand to Australia, completed multiple capital raises, and repositioned the company around rare and orphan neurodevelopmental indications — a strategy that culminated in the up to US$465m North American licensing deal with Acadia Pharmaceuticals for trofinetide, the foundation of what later became Daybue™.
He currently serves as Executive Chairman of BTC Health (ASX:BTC) and founding Director of Pharmaconnect.
Richard has closed deals with Eli Lilly, Acadia, Wyeth, Boots, Abbott, Orion Pharma, KV Pharma and Avanos Medical.
